Dentons (Paris and London) has assisted Théa Open Innovation with the signature of a partnership agreement with Link Biologics, including an equity investment from Théa Open Innovation, to develop Link_TSG6, a biologic drug for Dry Eye Disease (DED) worldwide (excluding Asia). Link_TSG6 is a biological drug based on human TSG-6, a protein that plays an intrinsic role to protect tissues from inflammatory damage.

Link Biologics will be responsible for all DED research and development up to the end of Phase 2 trials, with Théa Open Innovation taking over responsibilities, including commercialization of the drug thereafter.

This partnership is in line with Théa Group’s mission to provide cutting-edge ophthalmic solutions to eye care specialists and patients alike. Théa Open Innovation is a sister company of Laboratoires Théa. Its role is to identify, evaluate and support the most innovative development in eye care, throughlicensing agreements and/or equity investments.

The Dentons team was led by Jean-Marc Grosperrin (Partner), with Emmanuelle De Schepper (Of Counsel), (both Corporate) in Paris, and Neil Nicholson (Partner), Christopher Winn (Senior Associate) and Arjun Mehta (Associate) (all Corporate) in London.

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com